These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26165688)

  • 1. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
    Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
    Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
    Koh Y; Kim TM; Jeon YK; Kwon TK; Hah JH; Lee SH; Kim DW; Wu HG; Rhee CS; Sung MW; Kim CW; Kim KH; Heo DS
    Ann Oncol; 2009 Aug; 20(8):1414-9. PubMed ID: 19468031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
    Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Zhang Z; Jiang C; Hu L
    Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
    Bai ZL; Wang YY; Zhe H; He JL; Hai P
    Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
    Hasegawa K; Kato R; Torii Y; Ichikawa R; Oe S; Udagawa Y
    Int J Gynecol Cancer; 2011 Nov; 21(8):1479-85. PubMed ID: 21720251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
    Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
    Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
    Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
    Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
    BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
    Muallem MZ; Marnitz S; Richter R; Köhler C; Sehouli J; Arsenic R
    Anticancer Res; 2014 Jan; 34(1):401-6. PubMed ID: 24403494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ERCC1 and class III ß-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy.
    Zhang S; Li Q; Zhang Q; Wang J; Zhang H; Zhang Z; Wang Q; Yang X; Gu Y; Zhang H
    Int J Biol Markers; 2010; 25(3):141-9. PubMed ID: 20878620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimen.
    Leone J; Perez JE; Dominguez ME; Iturbe J; Leone JP; Mac Donnell MC; Grosman G; Vallejo CT; Leone BA; Zwenger AO
    Int J Biol Markers; 2016 Jul; 31(3):e300-8. PubMed ID: 27197582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
    Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there relationship between excision repair cross-complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin-based chemotherapy?
    Polat G; Yılmaz U; Anar C; Kömürcüoğlu B; Aydoğdu Z
    Indian J Cancer; 2015; 52(3):277-80. PubMed ID: 26905109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
    Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
    BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.